Bristol Myers Squibb (BMY) is currently trading at a low valuation, with a forward earnings multiple of around 10, making it the cheapest among its S&P 500 pharmaceutical peers. Despite a modest 8% return this year and a dividend yield exceeding 4%, investor sentiment is dampened by concerns over patent expirations for key drugs like Revlimid and Eliquis. However, the company’s recent performance indicates a potential turnaround, with revenue in Q1 2026 up 3% year-over-year, driven by strong growth in its newer product portfolio.
The market’s apprehension appears to overlook Bristol Myers’ promising pipeline and ongoing cost-saving initiatives projected to yield $2 billion annually by 2027. Notably, newer drugs such as Breyanzi and Camzyos are experiencing rapid revenue growth, which could offset losses from expiring patents.
For market professionals, the key takeaway is that Bristol Myers Squibb’s current valuation may not accurately reflect its growth potential. If the company can successfully navigate its patent challenges while expanding its newer therapies, it could present a compelling investment opportunity.
Source: fool.com